Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia.
Τίτλος | Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Roilides, E., Carlesse F., Tawadrous M., Leister-Tebbe H., Conte U., Raber S., Swanson R., Yan J. L., Aram J. A., & Queiroz-Telles F. |
Corporate Authors | Anidulafungin A8851008 Pediatric Study Group |
Journal | Pediatr Infect Dis J |
Volume | 39 |
Issue | 4 |
Pagination | 305-309 |
Date Published | 2020 04 |
ISSN | 1532-0987 |
Abstract | Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5-35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, and no treatment-related deaths occurred. End of intravenous therapy global response success rate was 68.8%. Pharmacokinetics were similar to adult patients. |
DOI | 10.1097/INF.0000000000002568 |
Alternate Journal | Pediatr Infect Dis J |
PubMed ID | 32032174 |
PubMed Central ID | PMC7182240 |